The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine

Journal of Veterinary Internal Medicine

Volumn 19, Issue 5, 2005, Pages 633-643

  Bergh, Mary Sarah ^a   Budsberg, Steven C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Arthritis; Cyclooxygenase; Nonsteroidal anti inflammatory drugs; Toxicity

Indexed keywords

ISOENZYME; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; ANIMAL DISEASE; DRUG ANTAGONISM; INFLAMMATION; PAIN; PHYSIOLOGY; REVIEW; SPECIES DIFFERENCE;

ANIMAL DISEASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; INFLAMMATION; ISOENZYMES; LEUKOTRIENES; PAIN; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 26844465915     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[633:TCNPCA]2.0.CO;2     Document Type: Review

References (178)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(Suppl 56):18-24.
2. Kessler FK, Kessler MR, Auyeung DJ, Ritter JK. Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases. Drug Metab Dispos 2002;30:324-330.
3. Paulson SK, Engel L, Reitz B, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999;27:1133-1142.
4. Jones RD, Baynes RE, Nimitz CT. Nonsteroidal anti-inflammatory drug toxicosis in dogs and cats: 240 Cases (1989-1990). J Am Vet Med Assoc 1992;201:475-477.
5. Frey HH, Rieh B. Pharmacokinetics of naproxen in the dog. Am J Vet Res 1981;42:1615-1617.
6. Hampshire VA, Doddy FM, Post LO, et al. Adverse drug event reports at the United States Food And Drug Administration Center for Veterinary Medicine. J Am Vet Med Assoc 2004;225:533-536.
7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
8. Konturek SJ, Pawlik W. Physiology and pharmacology of prostaglandins. Dig Dis Sci 1986;31:6S-19S.
9. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
10. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of the rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
11. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-454.
12. Smith TJ. Cyclooxygenases as the principal targets for the actions of NSAIDs. Rheum Dis Clin North Am 1998;24:501-523.
13. Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810-818.
14. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696.
15. Takahashi S, Shigeta J, Inoue H, et al. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol 1998;275:G1137-G1145.
16. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-25938.
17. Newton R, Seybold J, Kuitert LM, et al. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 1998;273:32312-32321.
18. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61-69.
19. Mitchell JA, Warner TD. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-1132.
20. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.
21. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
22. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
23. Sirois J, Richards JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-6388.
24. Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-249.
25. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.
26. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648.
27. Appleby SB, Ristimaki A, Neilson K, et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994;302(Pt 3):723-727.
28. Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293:391-400.
29. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: Similarities and differences. Scand J Rheumatol 2004;33:1-6.
30. Hood WF, Gierse JK, Isakson PC, et al. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 2003;63:870-877.
31. Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000;356:1373-1374.
32. Scott G, Rordorf C, Blood P, et al. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61(Suppl 1):242.
33. Mangold JB, Gu H, Rodriguez LC, et al. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004;32:566-571.
34. McCann ME, Andersen DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004;65:503-512.
35. Brideau C, Van SC, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
36. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 2000;61:802-810.
37. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
38. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 2002;63:1527-1531.
39. Sessions JK, Agnello KA, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on whole blood, gastric mucosal and synovial fluid prostaglandin synthesis in dogs with osteoarthritis. Am J Vet Res 2005;66:812-817.
40. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-12017.
41. Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997;283:1069-1075.
42. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-110.
43. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-1928.
44. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
45. Stock JL, Shinjo K, Burkhardt J, et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001;107:325-331.
46. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol 2001;64:327-363.
47. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95:13313-13318.
48. Beiche F, Scheuerer S, Brune K, et al. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165-169.
49. Goppelt-Struebe M, Beiche F. Cyclooxygenase-2 in the spinal cord: Localization and regulation after a peripheral inflammatory stimulus. Adv Exp Med Biol 1997;433:213-216.
50. Willingale HL, Gardiner NJ, McLymont N, et al. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 1997;122:1593-1604.
51. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-386.
52. Kaufmann WE, Worley PF, Taylor CV, et al. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev 1997;19:25-34.
53. Buvanendran A, Kroin J, Luk P, et al. Blood brain barrier penetration of oral rofecoxib, a potent and selective cyclooxygenase-2 inhibitor in dogs. Anesthesiology 2002;97:A465.
54. Buvanendran A, Kroin J, Luk P, et al. Central nervous system penetration of oral rofecoxib, a potent and selective cyclooxygenase-2 inhibitor in dogs. Anesthesiology 2001;95:A868.
55. Robinson DR, Tashjian AH Jr, Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 1975;56:1181-1188.
56. Pelletier JP, DiBattista JA, Roughley P, et al. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993;19:545-568.
57. Hardy MM, Seibert K, Manning PT, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789-1803.
58. O'Keefe RJ, Crabb ID, Puzas JE, Rosier RN. Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J Bone Miner Res 1992;7:397-404.
59. Fulkerson JP, Damiano P. Effect of prostaglandin E2 on adult pig articular cartilage slices in culture. Clin Orthop Relat Res Oct 1983;179:266-269.
60. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-718.
61. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997;99:1231-1237.
62. Bombardieri S, Cattani P, Ciabattoni G, et al. The synovial prostaglandin system in chronic inflammatory arthritis: Differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 1981;73:893-901.
63. Blanco FJ, Guitian R, Moreno J, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol 1999;26:1366-1373.
64. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-1247.
65. Spreng D, Sigrist N, Jungi T, et al. Nitric oxide metabolite production in the cranial cruciate ligament, synovial membrane, and articular cartilage of dogs with cranial cruciate ligament rupture. Am J Vet Res 2000;61:530-536.
66. Spreng D, Sigrist N, Schweighauser A, et al. Endogenous nitric oxide production in canine osteoarthritis: Detection in urine, serum, and synovial fluid specimens. Vet Surg 2001;30:191-199.
67. Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998;41:1275-1286.
68. Frean SP, Bryant CE, Froling IL, et al. Nitric oxide production by equine articular cells in vitro. Equine Vet J 1997;29:98-102.
69. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
70. Bamba H, Ota S, Kato A, et al. Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells. J Exp Clin Cancer Res 2000;19:219-223.
71. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther 2000;14(Suppl 1):44-49.
72. Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-649.
73. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
74. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518-523.
75. Rao CV, Simi B, Wynn TT, et al. Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res 1996;56:532-537.
76. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
77. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-4820.
78. McEntee MF, Cates JM, Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol 2002;39:428-436.
79. Khan KN, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
80. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
81. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-1280.
82. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
83. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
84. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
85. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-M78.
86. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-860.
87. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-4760.
88. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
89. Sorenmo K, Goldschmidt M, Shofer F, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004;2:13-23.
90. Bosetti C, Talamini R, Franceschi S, et al. Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 2003;88:672-674.
91. Collins LG, Tyler DE. Experimentally induced phenylbutazone toxicosis in ponies: Description of the syndrome and its prevention with synthetic prostaglandin E2. Am J Vet Res 1985;46:1605-1615.
92. Blikslager AT, Roberts MC, Argenzio RA. Prostaglandin-induced recovery of barrier function in porcine ileum is triggered by chloride secretion. Am J Physiol 1999;276:G28-G36.
93. Vonderhaar MA, Salisbury SK. Gastroduodenal ulceration associated with flunixin meglumine administration in three dogs. J Am Vet Med Assoc 1993;203:92-95.
94. MacDonald TM, Morant SV, Goldstein JL, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003;52:1265-1270.
95. Reed S. Nonsteroidal anti-inflammatory drug-induced duodenal ulceration and perforation in a mature rottweiler. Can Vet J 2002;43:971-972.
96. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 1982;27:624-635.
97. Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration. Inflamm Res 1998;47(Suppl 2):S102-S106.
98. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996;25:279-298.
99. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-492.
100. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
101. Gretzer B, Maricic N, Respondek M, et al. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001;132:1565-1573.
102. Moreau M, Daminet S, Martel-Pelletier J, et al. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J Vet Pharmacol Ther 2005;28:81-86.
103. Hirose M, Miwa H, Kobayashi O, et al. Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, JTE522, is also mediated by a PGE2-independent pathway. Aliment Pharmacol Ther 2002;16(Suppl 2):83-89.
104. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
105. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Br J Pharmacol 1998;123:795-804.
106. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15.
107. Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
108. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
109. Nantel F, Meadows E, Denis D, et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999;457:475-477.
110. Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999;103:953-961.
111. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999;34:96-101.
112. Harding P, Carretero OA, Beierwaltes WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens 2000;18:1107-1113.
113. Traynor TR, Smart A, Briggs JP, Schnermann J. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999;277:F706-F710.
114. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998;274:F481-F489.
115. Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000;36:276-281.
116. Whelton A. COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema. J Hypertens 2002;20(Suppl 6):S31-S35.
117. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol 1991;31:588-598.
118. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-976.
119. Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003;21:670-675.
120. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br 1981;63-B:185-189.
121. Goodman SB, Ma T, Genovese M, Lane SR. COX-2 selective inhibitors and bone. Int J Immunopathol Pharmacol 2003;16:201-205.
122. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-1415.
123. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995;313:36-46.
124. Zhang X, Morham SG, Langenbach R, et al. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res 2001;16:660-670.
125. Min YK, Rao Y, Okada Y, et al. Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J Bone Miner Res 1998;13:1066-1075.
126. Tokushima T, Sato T, Morita I, Murota S. Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast formation induced by parathyroid hormone. Adv Exp Med Biol 1997;433:307-309.
127. Tai H, Miyaura C, Pilbeam CC, et al. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 1997;138:2372-2379.
128. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352.
129. Fiorucci S, Antonelli E. Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents. Dig Liver Dis 2001;33(Suppl 2):S2-S7.
130. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
131. Hinz B, Kraus V, Pahl A, Brune K. Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages. Biochem Biophys Res Commun 2000;274:197-202.
132. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-3076.
133. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
134. Pratico D, Tillmann C, Zhang ZB, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001;98:3358-3363.
135. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004;43:519-525.
136. Verma S, Raj SR, Shewchuk L, et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001;104:2879-2882.
137. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.
138. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004;364:665-674.
139. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
140. Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91:197-208.
141. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996;16:107-122.
142. Gibb W, Sun M. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996;150:497-503.
143. Loftin CD, Trivedi DB, Tiano HF, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 2001;98:1059-1064.
144. Takizawa T, Horikoshi E, Kamata A. Role of the nitric oxide-cGMP system in the regulation of ductus arteriosus patency in fetal rats. J Vet Med Sci 1999;61:1277-1280.
145. Komhoff M, Wang JL, Cheng HF, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000;57:414-422.
146. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995;355:296-315.
147. Kaufmann WE, Worley PF, Pegg J, et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-2321.
148. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997;54:601-624.
149. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
150. Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: A possible site of prostaglandin synthesis responsible for fever. Brain Res 1996;733:263-272.
151. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1-beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-475.
152. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
153. in 't Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998;19:607-611.
154. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage 2002;23:S35-S40.
155. Pasinetti GM. Cyclooxygenase and Alzheimer's disease: Implications for preventive initiatives to slow the progression of clinical dementia. Arch Gerontol Geriatr 2001;33:13-28.
156. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107:27S-35S.
157. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
158. Halpin RA, Geer LA, Zhang KE, et al. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab Dispos 2000;28:1244-1254.
159. Uetrecht J. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev 2002;34:651-665.
160. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-1635.
161. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 2004;27:129-138.
162. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931.
163. Ulrich CM, Bigler J, Sibert J, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002;20:409-410.
164. Radmark OP. The molecular biology and regulation of 5-lipoxygenase. Am J Respir Crit Care Med 2000;161:S11-S15.
165. Peters-Golden M, Coffey M. Role of leukotrienes in antimicrobial defense of the lung. J Lab Clin Med 1998;132:251-257.
166. Skelly MM, Hawkey CJ. COX-LOX inhibition: Current evidence for an emerging new therapy. Int J Clin Pract 2003;57:301-304.
167. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem Pharmacol 2001;62:1433-1438.
168. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: Is two better than one? J Rheumatol 2001;28:2375-2382.
169. Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992;256:225-228.
170. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol Suppl 1997;49:15-19.
171. Brown JF, Hanson PJ, Whittle BJ. Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol 1992;223:103-104.
172. Coruzzi G, Coppelli G, Spaggiari S, et al. Gastroprotective effects of amtolmetin guacyl: A new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase. Dig Liver Dis 2002;34:403-410.
173. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
174. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998;59:1441-1446.
175. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
176. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.
177. Marnett LJ, Kalgutkar AS. Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future. Trends Pharmacol Sci 1999;20:465-469.
178. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-2072.